We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
- Authors
Ouellet, D.; Bramson, C.; Roman, D.; Remmers, A. E.; Randinitis, E.; Milton, A.; Gardner, M.
- Abstract
Aims Two studies were conduced to assess the effects of ketoconazole, a CYP3A4/5 inhibitor; fluconazole, a CYP2C9 inhibitor; and paroxetine, a CYP2D6 inhibitor, on lasofoxifene pharmacokinetics. Methods The first parallel group study was conducted in 45 healthy postmenopausal women (15 per group) to compare the pharmacokinetics of a single dose of lasofoxifene (0.25 mg) administered alone and in combination with ketoconazole (400 mg daily × 20 days) or fluconazole (400 mg daily × 20 days). Lasofoxifene was administered on day 2 and blood samples were collected serially for up to 456 h postdose (20 days). The second study enrolled 20 healthy postmenopausal women (10 per group) to compare the pharmacokinetics of a single dose of lasofoxifene (0.25 mg) alone and in combination with paroxetine (30 mg qd × 21 days). Lasofoxifene was given on day 8 of paroxetine treatment and blood samples were collected serially for up to 336 h postdose. Results All subjects completed the study and the treatments were well tolerated. Lasofoxifene Cmax and AUC ratios [90% confidence interval (CI)] with/without ketoconazole were 111% (98.4, 127) and 120% (105, 136), respectively, and were 91.3% (80.3, 104) and 104% (91.4, 118), respectively, with/without fluconazole. Lasofoxifene Cmax and AUC ratios (90% CI) with/without paroxetine were 118% (95.4, 146) and 135% (120, 152), respectively. Conclusions Coadministration of potent inhibitors of CYP3A4/5 and CYP2D6, but not CYP2C9, resulted in a moderate increase in lasofoxifene exposure. No dosage adjustment should be required when lasofoxifene is coadministered with ketoconazole, fluconazole, paroxetine or other agents that inhibit these CYP enzymes.
- Subjects
CYTOCHROME P-450; CHEMICAL inhibitors; KETOCONAZOLE; PHARMACOKINETICS; DRUG interactions; CLINICAL pharmacology
- Publication
British Journal of Clinical Pharmacology, 2007, Vol 63, Issue 1, p59
- ISSN
0306-5251
- Publication type
Article
- DOI
10.1111/j.1365-2125.2006.02709.x